ENDPOINTS

#ASCO25: In race with Merus, Bicara makes the case for two-year survival data

CHICAGO — Forced to play defense after its stock price fell 40% last month on competing data, Bicara hopes to win back some favor with new results for its head and neck cancer drug. In the ...

Jun 1, 2025 - 18:24
 0
#ASCO25: In race with Merus, Bicara makes the case for two-year survival data
CHICAGO — Forced to play defense after its stock price fell 40% last month on competing data, Bicara hopes to win back some favor with new results for its head and neck cancer drug. In the ...
Read More

Tags:

Previous Article

Celtic quiz: Test your knowledge about these fierce tribes once described by Jul...

Next Article

Avast, matey! 5 of the biggest pirate hauls in history

Related Posts

The preventive care rebrand

The preventive care rebrand

May 29, 2025  0

Astellas licenses Claudin18.2 ADC from China’s Evopoint Biosciences

Astellas licenses Claudin18.2 ADC from China’s Evopoint...

May 30, 2025  0

Trump administration reveals 'most favored nation' drug price country targets

Trump administration reveals 'most favored nation' drug...

May 20, 2025  0